RESUMO
BACKGROUND: Type 1 conventional dendritic cells (cDC1s) are characterized by their ability to induce potent CD8+ T cell responses. In efforts to generate novel vaccination strategies, notably against cancer, human cDC1s emerge as an ideal target to deliver antigens. cDC1s uniquely express XCR1, a seven transmembrane G protein-coupled receptor. Due to its restricted expression and endocytic nature, XCR1 represents an attractive receptor to mediate antigen-delivery to human cDC1s. METHODS: To explore tumor antigen delivery to human cDC1s, we used an engineered version of XCR1-binding lymphotactin (XCL1), XCL1(CC3). Site-specific sortase-mediated transpeptidation was performed to conjugate XCL1(CC3) to an analog of the HLA-A*02:01 epitope of the cancer testis antigen New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1). While poor epitope solubility prevented isolation of stable XCL1-antigen conjugates, incorporation of a single polyethylene glycol (PEG) chain upstream of the epitope-containing peptide enabled generation of soluble XCL1(CC3)-antigen fusion constructs. Binding and chemotactic characteristics of the XCL1-antigen conjugate, as well as its ability to induce antigen-specific CD8+ T cell activation by cDC1s, was assessed. RESULTS: PEGylated XCL1(CC3)-antigen conjugates retained binding to XCR1, and induced cDC1 chemoattraction in vitro. The model epitope was efficiently cross-presented by human cDC1s to activate NY-ESO-1-specific CD8+ T cells. Importantly, vaccine activity was increased by targeting XCR1 at the surface of cDC1s. CONCLUSION: Our results present a novel strategy for the generation of targeted vaccines fused to insoluble antigens. Moreover, our data emphasize the potential of targeting XCR1 at the surface of primary human cDC1s to induce potent CD8+ T cell responses.
Assuntos
Antígenos de Neoplasias , Vacinas Anticâncer , Células Dendríticas , Neoplasias Esofágicas , Carcinoma de Células Escamosas do Esôfago , Linfocinas , Proteínas de Membrana , Sialoglicoproteínas , Antígenos de Neoplasias/administração & dosagem , Antígenos de Neoplasias/imunologia , Linfócitos T CD8-Positivos/imunologia , Vacinas Anticâncer/administração & dosagem , Vacinas Anticâncer/imunologia , Apresentação Cruzada , Células Dendríticas/imunologia , Epitopos/imunologia , Neoplasias Esofágicas/imunologia , Neoplasias Esofágicas/terapia , Carcinoma de Células Escamosas do Esôfago/imunologia , Carcinoma de Células Escamosas do Esôfago/terapia , Humanos , Linfocinas/administração & dosagem , Linfocinas/imunologia , Masculino , Proteínas de Membrana/administração & dosagem , Proteínas de Membrana/imunologia , Sialoglicoproteínas/administração & dosagem , Sialoglicoproteínas/imunologiaRESUMO
Purpose: The aim of this study was the investigation of the effect of sulglycotide (SOS), a polysulfated glycopeptide derived from porcine duodenal mucin, for the treatment of dry eye disease. Methods: NOD.B10.H2b mice were exposed to an air draft for 10 days, and, simultaneously, scopolamine hydrobromide was injected subcutaneously. The mice were randomly divided into nine groups as follows: four kinds of SOS formulations and three kinds of commercial medicine. After 10 days of treatment, we estimated the effect of treatment on tear production, epithelium stabilization, mucin secretion, and inflammation. Results: The desiccation stress significantly decreased tear production and corneal epithelium stabilization, as well as markedly decreased the numbers of goblet cells and mucin-stained cells in conjunctiva. However, the topical 4% SOS eye drops markedly increased tear production and corneal stabilization, which recovered to baseline levels. In addition, topical 4% SOS significantly induced an increase in the numbers of goblet cells and the expression of membrane-associated mucins including MUC1, MUC4, and MUC16, as well as the gel-forming mucin, MUC5AC. Furthermore, SOS formulations provided anti-inflammatory improvement in a dose-dependent manner. Conclusions: In summary, we suggest that a new ophthalmic pharmaceutical formulation, topical sulglycotide, enhances the ocular mucin secretion in dry eye disease and can be used as a new ophthalmic pharmaceutical material to treat dry eye disease.
Assuntos
Antiulcerosos/uso terapêutico , Síndromes do Olho Seco/tratamento farmacológico , Mucinas/metabolismo , Sialoglicoproteínas/uso terapêutico , Lágrimas/metabolismo , Administração Oftálmica , Animais , Antiulcerosos/administração & dosagem , Dessecação , Modelos Animais de Doenças , Composição de Medicamentos , Síndromes do Olho Seco/induzido quimicamente , Síndromes do Olho Seco/metabolismo , Ensaio de Imunoadsorção Enzimática , Técnica Indireta de Fluorescência para Anticorpo , Células Caliciformes/efeitos dos fármacos , Imuno-Histoquímica , Camundongos , Camundongos Endogâmicos NOD , Antagonistas Muscarínicos/toxicidade , Soluções Oftálmicas , Estresse Oxidativo , Reação em Cadeia da Polimerase em Tempo Real , Escopolamina/toxicidade , Sialoglicoproteínas/administração & dosagemRESUMO
In this study, open tibial fracture surgery was performed on mice with ovariectomy induced osteoporosis to investigate the effect of a treatment with sialoglycoprotein isolated from Carassius auratus eggs (Ca-SGP) on fracture healing. Dynamic histological analysis showed that Ca-SGP promoted the generation of cartilage callus on day 5 post-surgery, then facilitated the transformation of the cartilage callus to bony callus on days 11 and 24 post-surgery, and enhanced the remodeling of bony callus on 35 day post-surgery. Moreover, Ca-SGP significantly decreased the secretion of TNF-α and IL-1ß in serum on day 5 post-surgery, thus inhibiting the negative spread of the inflammatory reaction. On day 11 post-surgery, Ca-SGP clearly decreased the serum level and the mRNA expression of Aggrecan but also increased the secretion and the expression of VEGF and MMP13, thus promoting the degradation of the cartilage matrix and vascular invasion. On day 24 post-surgery, Ca-SGP remarkably increased the mRNA expression of osteogenesis markers Col1a and OCN, and increased callus BV/TV and Tb.N, this facilitating the formation of woven bone. On day 35 post-surgery, Ca-SGP enhanced the transformation of woven bone into lamellar bone and improved the callus biomechanical property. In conclusion, Ca-SGP promoted fracture healing in osteoporotic mice by accelerating endochondral ossification.
Assuntos
Proteínas de Peixes/administração & dosagem , Consolidação da Fratura/efeitos dos fármacos , Carpa Dourada , Osteoporose/tratamento farmacológico , Óvulo/química , Sialoglicoproteínas/administração & dosagem , Agrecanas/genética , Agrecanas/metabolismo , Animais , Cartilagem/efeitos dos fármacos , Cartilagem/lesões , Cartilagem/fisiopatologia , Cartilagem/cirurgia , Feminino , Proteínas de Peixes/isolamento & purificação , Humanos , Interleucina-1beta/sangue , Interleucina-1beta/genética , Camundongos , Camundongos Endogâmicos C57BL , Osteoporose/metabolismo , Osteoporose/cirurgia , Ovariectomia , Sialoglicoproteínas/isolamento & purificação , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/genética , Fator A de Crescimento do Endotélio Vascular/genética , Fator A de Crescimento do Endotélio Vascular/metabolismoRESUMO
Osteoporosis is a common disease in the elderly, which is related to fracture healing delay. In this study, the effects of treatment with sialoglycoprotein isolated from the eggs of Gadus morhua (Gm-SGP) on tibial fracture healing in ovariectomized (OVX) osteoporotic female C57BL/6J mice for 56 days post-fracture were investigated. The result showed that Gm-SGP treatment significantly increased serum angiogenic factors and bone formation markers on day 5 and 11 post-fracture when compared with the OVX group. In addition, histological results in the Gm-SGP group showed a stronger endochondral ossification, a stronger bony consolidation and a stronger bony callus remodeling capability on day 11, 24 and 35 post-fracture, respectively, in comparison with the OVX group. Meanwhile, micro-computerized tomography revealed that the Gm-SGP group had stronger bony callus remodeling capability as evidenced by higher BV/TV and Tb.N but lower Tb.Sp and shorter lengths of callus maximum cross section than the OVX group on day 24 post-fracture. Besides, the tibial callus bending stiffness was significantly enhanced in the Gm-SGP group as compared with the OVX group on day 56 post-fracture. Moreover, gene expression suggested that Gm-SGP promoted vascular invasion and endochondral ossification on day 11 post-fracture as well as bone formation on day 11 and 24 post-fracture via up-regulating the expression of angiogenesis factors (including VEGF, PDGF and Ang1), entochondrostosis factors (including Col2a1, Aggrecan, Col10a1 and MMP-13) and osteogenesis markers (including Col1a1, BMP-2 and OCN). This research suggests that Gm-SGP significantly improve fracture healing which is delayed by OVX-induced osteoporosis. The present study may contribute to providing important implications for the utilization of Gm-SGP from fish eggs as a functional food to enhance fracture healing.
Assuntos
Ovos/análise , Proteínas de Peixes/administração & dosagem , Consolidação da Fratura/efeitos dos fármacos , Fraturas Ósseas/tratamento farmacológico , Osteoporose/complicações , Sialoglicoproteínas/administração & dosagem , Animais , Feminino , Proteínas de Peixes/isolamento & purificação , Fraturas Ósseas/etiologia , Fraturas Ósseas/fisiopatologia , Gadus morhua , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Osteogênese/efeitos dos fármacos , Osteoporose/fisiopatologia , Sialoglicoproteínas/isolamento & purificaçãoRESUMO
In the current study, ovariectomized (OVX) rats and the senescence-accelerated mouse strain P6 (SAMP6) were employed to establish models of postmenopausal osteoporosis and senile osteoporosis, respectively. The effects of treatment with sialoglycoprotein isolated from the eggs of Carassius auratus (Ca-SGP) on these two types of osteoporosis were investigated in vivo. Results showed that Ca-SGP significantly increased bone mineral density, ameliorated trabecular bone microstructure, and improved bone biomechanical properties in both OVX rats and SAMP6. The osteogenesis related Wnt/ß-catenin pathway was targeted to study the underlying mechanism of Ca-SGP activity. In postmenopausal osteoporosis, Ca-SGP suppressed the activation of Wnt/ß-catenin signal via down-regulating the expression of key genes including LRP5, ß-catenin, and Runx2, suggesting that overactive osteogenesis was controlled by Ca-SGP. The bone formation was sharply weakened in senile osteoporosis, whereas Ca-SGP treatment promoted osteoblast activity by stimulating the Wnt/ß-catenin signal. In conclusion, Ca-SGP ameliorated these two types of osteoporosis by normalizing bone anabolism.
Assuntos
Ovos/análise , Proteínas de Peixes/administração & dosagem , Osteoporose Pós-Menopausa/tratamento farmacológico , Osteoporose/tratamento farmacológico , Sialoglicoproteínas/administração & dosagem , Via de Sinalização Wnt/efeitos dos fármacos , Animais , Osso e Ossos/efeitos dos fármacos , Osso e Ossos/metabolismo , Feminino , Proteínas de Peixes/isolamento & purificação , Regulação da Expressão Gênica , Carpa Dourada , Humanos , Masculino , Camundongos , Osteoblastos/efeitos dos fármacos , Osteoblastos/metabolismo , Osteoporose/genética , Osteoporose/metabolismo , Osteoporose Pós-Menopausa/genética , Osteoporose Pós-Menopausa/metabolismo , Ratos , Sialoglicoproteínas/isolamento & purificação , beta Catenina/metabolismoRESUMO
OBJECTIVE: To observe the effects of Alpha-lipoic acid (ALA) on oxidative stress (OS) in vivo and urinary podocalyxin (PCX, the glomerular podocyte marker protein) excretion in type 2 diabetics and explore its possible protective mechanisms on glomerular podocytes. METHODS: Thirty-six type 2 diabetics were recruited as observation group and treated with ALA on the basis of initial therapy for six months, and 30 healthy subjects were selected as control group. FBG, HbA1c, serum glutathione peroxidase (SGSH-Px), superoxide dismutase (SSOD) activity, urinary malondialdehyde (UMDA), 8-hydroxy-deoxyguanosine (U8-OHdG), albumin (UALB), creatinine (UCr) and urinary PCX (UPCX) were determined at baseline and after six months' observation. RESULTS: Compared with the control group, the ratios of UMDA/UCr (UMCR), U8-OHdG/UCr (U8CR), UALB/UCr (UACR) and UPCX/UCr (UPCR) increased markedly, SGSH-Px and SSOD decreased significantly in the diabetics (P<0.01); after sixth month treatment, the levels of UMCR, U8CR, UACR and UPCR reduced and SGSH-Px and SSOD increased markedly in the observation group (P<0.05) with no significant changes in FBG and HbA1c. UPCR had positive correlation with UACR, UMCR and U8CR (r=0.720, r=0.661, r=0.698, P<0.01), and negative correlation with SGSH-Px and SSOD in the diabetics (r=-0.608, r=-0.559, P<0.01). CONCLUSION: ALA can provide some protection against glomerular podocyte injury in type 2 diabetics, which may be related partly to its effects in alleviating enhanced OS and strengthening antioxidant ability in vivo.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Sialoglicoproteínas/administração & dosagem , Ácido Tióctico/administração & dosagem , Adulto , Albuminúria/diagnóstico , Albuminúria/epidemiologia , Biomarcadores/metabolismo , Glicemia/análise , Glicemia/efeitos dos fármacos , Estudos de Casos e Controles , Diabetes Mellitus Tipo 2/diagnóstico , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Hemoglobinas Glicadas/metabolismo , Humanos , Modelos Lineares , Masculino , Malondialdeído/urina , Pessoa de Meia-Idade , Valores de Referência , Sialoglicoproteínas/urina , Superóxido Dismutase/metabolismo , Resultado do TratamentoRESUMO
Decades of research in bioengineering have resulted in the development of many types of 3-dimentional (3D) scaffolds for use as drug delivery systems (DDS) and for tissue regeneration. Scaffolds may be comprised of different natural fibers and synthetic polymers as well as ceramics in order to exert the most beneficial attributes including biocompatibility, biodegradability, structural integrity, cell infiltration and attachment, and neovascularization. Type I collagen scaffolds meet most of these criteria. In addition, type I collagen binds integrins through RGD and non-RGD sites which facilitates cell migration, attachment, and proliferation. Type I collagen scaffolds can be used for bone tissue repair when they are coated with osteogenic proteins such as bone morphogenic protein (BMP) and bone sialoprotein (BSP). BSP, a small integrin-binding ligand N-linked glycoprotein (SIBLING), has osteogenic properties and plays an essential role in bone formation. BSP also mediates mineral deposition, binds type I collagen with high affinity, and binds α v ß 3 and α v ß 5 integrins which mediate cell signaling. This paper reviews the emerging evidence demonstrating the efficacy of BSP-collagen scaffolds in bone regeneration.
Assuntos
Regeneração Óssea/efeitos dos fármacos , Regeneração Óssea/fisiologia , Colágeno/química , Implantes de Medicamento/administração & dosagem , Osteoblastos/fisiologia , Sialoglicoproteínas/administração & dosagem , Alicerces Teciduais/tendências , Animais , Implantes de Medicamento/química , Desenho de Equipamento , Humanos , Osteoblastos/citologia , Sialoglicoproteínas/químicaRESUMO
A lot of research has been carried out in the last decade to find a cure for neurodegenerative diseases especially Parkinson's disease but to little avail. In this study we have demonstrated the use of poly(lactic-co-glycolic acid) (PLGA)/collagen biodegradable microparticles formed using water-in-oil-in-water (W/O/W) double emulsion method, as a neurotrophic factor delivery vehicle. The microparticles were encapsulated with glial cell-derived neurotrophic factor (GDNF) fused with collagen binding peptide (CBP) immobilized to the inner collagen phase. The novelty lies in the strict regulation of release of GDNF-CBP from the microparticles as compared to a burst release from standard microparticles. The microparticles were demonstrated to be non-cytotoxic till 300 µg/2 × 105 cells and revealed a maximum release of 250 ng GDNF-CBP/mg microparticles in 0.3% collagenase. Differentiation of neural progenitor cells (NPCs) into mature neurons was demonstrated by co-culturing microparticles with cells in a medium containing collagenase which enabled the release of encapsulated GDNF-CBP, signaling the differentiation of NPCs into microtubule-associated protein 2 (MAP2)-expressing neurons. The successful ability of these microparticles to deliver neurotrophic factors and allow differentiation of NPCs into mature neurons provides some scope in its use for the treatment of Parkinson's disease and other neurodegenerative diseases.
Assuntos
Colágeno/química , Fator Neurotrófico Derivado de Linhagem de Célula Glial/química , Ácido Láctico/química , Fragmentos de Peptídeos/química , Ácido Poliglicólico/química , Sialoglicoproteínas/química , Diferenciação Celular , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Fator Neurotrófico Derivado de Linhagem de Célula Glial/administração & dosagem , Humanos , Células-Tronco Neurais/citologia , Células-Tronco Neurais/efeitos dos fármacos , Neurônios/citologia , Fragmentos de Peptídeos/administração & dosagem , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/química , Sialoglicoproteínas/administração & dosagemRESUMO
Induction of potent mucosal immune response is a goal of current vaccine strategies against mucus-infectious pathogens such as Coxsackievirus B3 type (CVB3). We previously showed that administration of lymphotactin (LTN) as an adjuvant could enhance the specific immune responses against a mucosal gene vaccine, chitosan-pVP1, against CVB3. To optimize the coadministration mode of the mucosal adjuvant, we compared the mucosal immune responses induced by chitosan-DNA vaccine with different combinations of the target VP1 antigen gene and the adjuvant LTN gene. The two genes were either cloned in separate vectors or coexpressed as a fusion or bicistron protein in the same vector before encapsulation in chitosan nanoparticles. Four doses of various adjuvant-combined chitosan-DNA were intranasally administrated to mice before challenge with CVB3. The results indicated that chitosan-formulated pVP1-LTN fusion plasmid exhibited very weak improvement of CVB3-specific immune responses. Although the bicistronic coexpression of LTN with VP1 was expected to be powerful, this combination had enhanced effects on serum IgG and systemic T cell immune responses, but not on mucosal T cell immunity. Coimmunization with VP1 and LTN as separate chitosan-DNA formulation remarkably enhanced antibody and T cell immune responses both in systemic and mucosal immune compartments, leading to the most desirable preventive effect on viral myocarditis. Taken together, how the adjuvant is combined with the target antigen has a strong influence on the mucosal immune responses induced by mucosal DNA vaccines.
Assuntos
Adjuvantes Imunológicos/administração & dosagem , Antígenos Virais/administração & dosagem , Infecções por Coxsackievirus/prevenção & controle , Imunidade nas Mucosas/efeitos dos fármacos , Linfocinas/administração & dosagem , Miocardite/imunologia , Sialoglicoproteínas/administração & dosagem , Vacinas de DNA/administração & dosagem , Adjuvantes Imunológicos/genética , Adjuvantes Imunológicos/farmacologia , Animais , Anticorpos Antivirais/sangue , Antígenos Virais/genética , Western Blotting , Quitosana/administração & dosagem , Quitosana/imunologia , Infecções por Coxsackievirus/imunologia , Ensaio de Imunoadsorção Enzimática , ELISPOT , Imunidade nas Mucosas/imunologia , Estimativa de Kaplan-Meier , Linfocinas/genética , Linfocinas/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Miocardite/virologia , Plasmídeos/administração & dosagem , Plasmídeos/genética , Sialoglicoproteínas/genética , Sialoglicoproteínas/farmacologia , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Vacinas de DNA/imunologiaRESUMO
Oral administration of edible bird's nest extract (EBNE) improved bone strength and calcium concentration in the femur of ovariectomized rats. Dermal thickness was also increased by EBNE supplementation, whereas EBNE administration did not affect the serum estradiol concentration. These results suggest that EBNE is effective for the improvement of bone loss and skin aging in postmenopause all women.
Assuntos
Densidade Óssea , Estradiol/análise , Fêmur/química , Osteoporose/prevenção & controle , Animais , Proteínas Aviárias/administração & dosagem , Proteínas Aviárias/metabolismo , Aves , Colágeno/análise , Dieta , Dietoterapia , Modelos Animais de Doenças , Estradiol/biossíntese , Estradiol/deficiência , Feminino , Glicosaminoglicanos/administração & dosagem , Glicosaminoglicanos/metabolismo , Humanos , Osteoporose/dietoterapia , Osteoporose/fisiopatologia , Ovariectomia/efeitos adversos , Ratos , Ratos Sprague-Dawley , Sialoglicoproteínas/administração & dosagem , Sialoglicoproteínas/metabolismo , Envelhecimento da PeleRESUMO
Although interleukin-10 (IL-10) is commonly regarded as an immunosuppressive cytokine, a wealth of evidence is accumulating that IL-10 also possesses some immunostimulating antitumor properties. Previous studies demonstrated that forced expression of the IL-10 gene in tumor cells could unexpectedly produce antitumor effects. In this study, we explored the tumorigenesis of EG7 cells transduced with IL-10 gene. In vivo, IL-10 gene transfer reduced tumorigenic capacity of EG7 cells and prolonged survival of the EG7 tumor-bearing mice. It was found that the cytotoxicities of cytotoxic T lymphocytes (CTL) and natural killer cells (NK cells) were enhanced. Assessment of the immune status of the animals showed prevalence of a systemic and tumor-specific Th2 response (high levels of IL-4 and IL-10). To improve the therapeutic efficacy, we combined with intratumoral injection of adenovirus-mediated lymphotactin (Ad-Lptn) into the overestablished EG7 tumor model. More significant inhibition of tumor growth were observed in EG7 tumor-bearing mice that received combined treatment with IL-10 and Lptn gene than those of mice treated with IL-10 or Lptn gene alone. The highest NK cells and CTL activity was induced in the combined therapy group, increasing the production of IL-2 and interferon-γ (IFN-γ) significantly but decreasing the expression of immune suppressive cells (CD4(+)Foxp3(+) Treg cells and Gr1(+)CD11b(+) MDSCs). The necrosis of tumor cells was markedly observed in the tumor tissues, accompanying with strongest expression of Mig (monokine induced by interferon-gamma) and IP-10 (interferon-inducible protein 10), weakest expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinases-2 (MMP-2). In vivo, depletion analysis demonstrated that CD8(+) T cells and NK cells were the predominant effector cell subset responsible for the antitumor effect of IL-10 or Lptn gene. These findings may provide a potential strategy to improve the antitumor efficacy of IL-10 and Lptn.
Assuntos
Interleucina-10/genética , Linfocinas/genética , Neoplasias Experimentais/genética , Neoplasias Experimentais/imunologia , Sialoglicoproteínas/genética , Adenoviridae/genética , Animais , Linhagem Celular Tumoral , Separação Celular , Quimiocina CXCL10/biossíntese , Quimiocina CXCL10/imunologia , Quimiocina CXCL9/biossíntese , Quimiocina CXCL9/imunologia , Feminino , Citometria de Fluxo , Técnicas de Transferência de Genes , Terapia Genética , Vetores Genéticos , Imuno-Histoquímica , Imunoterapia/métodos , Interleucina-10/administração & dosagem , Interleucina-10/imunologia , Células Matadoras Naturais/imunologia , Linfocinas/administração & dosagem , Linfocinas/imunologia , Metaloproteinase 2 da Matriz/biossíntese , Metaloproteinase 2 da Matriz/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Neoplasias Experimentais/patologia , Gravidez , RNA Mensageiro/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Sialoglicoproteínas/administração & dosagem , Sialoglicoproteínas/imunologia , Linfócitos T Citotóxicos/imunologia , Transdução Genética , Fator A de Crescimento do Endotélio Vascular/biossíntese , Fator A de Crescimento do Endotélio Vascular/imunologiaRESUMO
The chemokine, lymphotactin (LTN), was tested as a molecular adjuvant using bicistronic DNA vaccines encoding the protective Yersinia capsular (F1) antigen and virulence antigen (V-Ag) as a F1-V fusion protein. The LTN-encoding F1-V or V-Ag vaccines were given by the intranasal (i.n.) or intramuscular (i.m.) routes, and although serum IgG and mucosal IgA antibodies (Abs) were induced, F1-Ag boosts were required for robust anti-F1-Ag Abs. Optimal efficacy against pneumonic plague was obtained in mice i.m.-, not i.n.-immunized with these DNA vaccines. These vaccines stimulated elevated Ag-specific Ab-forming cells and mixed Th cell responses, with Th17 cells markedly enhanced by i.m. immunization. These results show that LTN can be used as a molecular adjuvant to enhance protective immunity against plague.
Assuntos
Vacina contra a Peste/administração & dosagem , Vacina contra a Peste/imunologia , Peste/prevenção & controle , Vacinas de DNA/administração & dosagem , Vacinas de DNA/imunologia , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/genética , Administração Intranasal , Animais , Anticorpos Antibacterianos/análise , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/genética , Antígenos de Bactérias/imunologia , Proteínas de Bactérias/genética , Proteínas de Bactérias/imunologia , Feminino , Imunidade nas Mucosas , Imunização Secundária/métodos , Imunoglobulina A/análise , Imunoglobulina G/sangue , Injeções Intramusculares , Linfocinas/administração & dosagem , Linfocinas/genética , Camundongos , Camundongos Endogâmicos BALB C , Peste/imunologia , Vacina contra a Peste/genética , Proteínas Citotóxicas Formadoras de Poros/genética , Proteínas Citotóxicas Formadoras de Poros/imunologia , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/imunologia , Sialoglicoproteínas/administração & dosagem , Sialoglicoproteínas/genética , Análise de Sobrevida , Vacinas de DNA/genética , Vacinas Sintéticas/genética , Vacinas Sintéticas/imunologiaRESUMO
BACKGROUND AND PURPOSE: This study investigated the effects of intravenous recombinant Fv-Hsp70 protein on infarction volume and behavior after experimental ischemic stroke. METHODS: Focal cerebral ischemia was produced by occluding the middle cerebral artery using the intraluminal suture technique. Rats subjected to 2 hours of focal ischemia were allowed to survive 24 hours. At 2(1/4) hours and 3 hours after onset of ischemia, Fv-Hsp70 recombinant protein (0.5 mg/kg) or saline was injected through the tail vein. Sensorimotor function and infarction volume were assessed at 24 hours after ischemia. RESULTS: Administration of Fv-Hsp70 after focal cerebral ischemia significantly decreased infarct volume by 68% and significantly improved sensorimotor function compared with the saline-treated control group. Western blots showed Fv-Hsp70 in ischemic but not in control brain; and Fv-Hsp70 suppressed endogenous Hsp70. CONCLUSIONS: Fv-Hsp70 protected the ischemic brain in this experimental stroke model.
Assuntos
Isquemia Encefálica/tratamento farmacológico , Proteínas de Choque Térmico HSP70/administração & dosagem , Fragmentos de Imunoglobulinas/administração & dosagem , Linfocinas/administração & dosagem , Fármacos Neuroprotetores/administração & dosagem , Proteínas Recombinantes/administração & dosagem , Sialoglicoproteínas/administração & dosagem , Animais , Isquemia Encefálica/patologia , Proteínas de Choque Térmico HSP70/fisiologia , Humanos , Fragmentos de Imunoglobulinas/fisiologia , Injeções Intraventriculares , Linfocinas/fisiologia , Masculino , Ratos , Ratos Sprague-Dawley , Sialoglicoproteínas/fisiologiaRESUMO
Although considerable efforts have been made in the discovery of new agents for cancer treatment, several promising therapeutics cannot be applied systemically because of their severe side effects. This is the case for various recombinant pro-inflammatory cytokines that, despite their potent anti-cancer activity, can not find their way to clinical exploitation due to their devastating toxicity shown during dose escalation to therapeutically active concentrations. To circumvent these problems, an elegant and efficient way to accumulate therapeutic agents at the tumor site, thus reducing systemic side effects, is their conjugation to tumor-specific antibodies. Here, we review preclinical data about immunocytokines conjugated to a promising single-chain human antibody that selectively targets tumor-associated stroma and blood vessels by binding with high affinity and specificity to the extra domain-B (EDB) of fibronectin.
Assuntos
Antineoplásicos/administração & dosagem , Citocinas/administração & dosagem , Sistemas de Liberação de Medicamentos , Linfocinas/administração & dosagem , Neoplasias/tratamento farmacológico , Sialoglicoproteínas/administração & dosagem , Animais , Anticorpos Monoclonais/imunologia , Anticorpos Antineoplásicos/imunologia , Especificidade de Anticorpos , Fibronectinas/química , Fibronectinas/imunologia , Humanos , Camundongos , Camundongos Nus , Estrutura Terciária de Proteína/fisiologiaRESUMO
Rheumatoid arthritis (RA) has severe and lasting effects on quality of life. This review (1) describes the disease progression, disability, and joint destruction that seriously alter a patient's quality of life, and (2) explains how the interleukin-1 receptor antagonist (IL-1Ra), anakinra, retards the progress of disease, thereby improving outcomes. Relevant articles were reviewed with a focus on RA, anakinra, and functional and quality-of-life outcomes. In randomized, controlled trials, the IL-1Ra anakinra provided meaningful benefits for patients with active RA, such as decreased signs and symptoms of disease, slower radiographic disease progression, reduced disability, and improved health-related quality of life. The biologic agent, anakinra, provides to patients with RA a valuable treatment option that has a positive impact on both function and quality of life.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Qualidade de Vida , Receptores de Interleucina-1/antagonistas & inibidores , Proteínas Recombinantes/uso terapêutico , Sialoglicoproteínas/uso terapêutico , Antirreumáticos/administração & dosagem , Artrite Reumatoide/psicologia , Humanos , Proteína Antagonista do Receptor de Interleucina 1 , Ensaios Clínicos Controlados Aleatórios como Assunto , Proteínas Recombinantes/administração & dosagem , Sialoglicoproteínas/administração & dosagemAssuntos
Técnicas de Transferência de Genes , Terapia Genética/métodos , Nefropatias/terapia , Transplante de Células-Tronco , Células-Tronco , Animais , Células da Medula Óssea/citologia , Sangue Fetal/citologia , Glucosilceramidase/administração & dosagem , Glucosilceramidase/genética , Glucuronidase/administração & dosagem , Glucuronidase/genética , Humanos , Molécula 1 de Adesão Intercelular , Proteína Antagonista do Receptor de Interleucina 1 , Nefropatias/fisiopatologia , Medicina Regenerativa , Sialoglicoproteínas/administração & dosagem , Sialoglicoproteínas/genéticaRESUMO
UNLABELLED: We report on a patient with chronic infantile neurological cutaneous and articular (CINCA) syndrome. Sequence analysis revealed a novel missense mutation in exon 4 of the CIAS1 gene. The patient was unresponsive to several treatments including prednisolone, immunosuppressants (azathioprine and cyclosporin), disease-modifying antirheumatic drugs (DMARDs: penicillamine, salazopyrin and methotrexate) and the tumour necrosis factor-alpha (TNF-a)-blocker infliximab. At 32 mo of age, administration of the recombinant human interleukin-1 receptor antagonist anakinra commenced, which caused an immediate and marked improvement in the clinical symptoms and laboratory test results. Continuous inhibition of the inflammation required a dose of 1.0 mg/kg every 12 h. CONCLUSION: Following the diagnosis of CINCA syndrome, anakinra treatment should be commenced as the first line of therapy.
Assuntos
Antirreumáticos/uso terapêutico , Proteínas de Transporte/genética , Doenças do Sistema Nervoso Central , Éxons/genética , Febre , Inflamação , Mutação Puntual/genética , Sialoglicoproteínas/uso terapêutico , Urticária , Antirreumáticos/administração & dosagem , Doenças do Sistema Nervoso Central/complicações , Doenças do Sistema Nervoso Central/tratamento farmacológico , Doenças do Sistema Nervoso Central/genética , Ensaio de Imunoadsorção Enzimática , Feminino , Febre/complicações , Febre/tratamento farmacológico , Febre/genética , Humanos , Recém-Nascido , Inflamação/complicações , Inflamação/tratamento farmacológico , Inflamação/genética , Injeções Subcutâneas , Proteína Antagonista do Receptor de Interleucina 1 , Proteína 3 que Contém Domínio de Pirina da Família NLR , Sialoglicoproteínas/administração & dosagem , Síndrome , Urticária/complicações , Urticária/tratamento farmacológico , Urticária/genéticaRESUMO
Tumor cells secreting IL-1beta are invasive and metastatic, more than the parental line or control mock-transfected cells, and concomitantly induce in mice general immune suppression of T cell responses. Suppression strongly correlates with accumulation in the peripheral blood and spleen of CD11b+/Gr-1+ immature myeloid cells and hematological alterations, such as splenomegaly, leukocytosis, and anemia. Resection of large tumors of IL-1beta-secreting cells restored immune reactivity and hematological alterations within 7-10 days. Treatment of tumor-bearing mice with the physiological inhibitor of IL-1, the IL-1R antagonist, reduced tumor growth and attenuated the hematological alterations. Depletion of CD11b+/Gr-1+ immature myeloid cells from splenocytes of tumor-bearing mice abrogated suppression. Despite tumor-mediated suppression, resection of large tumors of IL-1beta-secreting cells, followed by a challenge with the wild-type parental cells, induced resistance in mice; protection was not observed in mice bearing tumors of mock-transfected fibrosarcoma cells. Altogether, we show in this study that tumor-derived IL-1beta, in addition to its proinflammatory effects on tumor invasiveness, induces in the host hematological alterations and tumor-mediated suppression. Furthermore, the antitumor effectiveness of the IL-1R antagonist was also shown to encompass restoration of hematological alterations, in addition to its favorable effects on tumor invasiveness and angiogenesis that have previously been described by us.
Assuntos
Antígeno CD11b , Células Mieloides/imunologia , Neoplasias Experimentais/imunologia , Receptores de Quimiocinas , Linfócitos T/imunologia , Animais , Técnicas de Cocultura , Proteína Antagonista do Receptor de Interleucina 1 , Interleucina-1/antagonistas & inibidores , Interleucina-1/metabolismo , Camundongos , Invasividade Neoplásica/imunologia , Invasividade Neoplásica/prevenção & controle , Neoplasias Experimentais/metabolismo , Neoplasias Experimentais/patologia , Neovascularização Patológica/tratamento farmacológico , Receptores de Interleucina-1/antagonistas & inibidores , Sialoglicoproteínas/administração & dosagem , Sialoglicoproteínas/farmacologia , Baço/citologia , Carga Tumoral/efeitos dos fármacosRESUMO
This report describes statistical validation methods implemented on assay data for inhibition of subcellular redistribution of nuclear factor kappaB (NF kappaB) in HeLa cells. We quantified cellular inhibition of cytoplasmic-nuclear translocation of NF kappaB in response to a range of concentrations of interleukin-1 (IL-1) receptor antagonist in the presence of IL-1alpha using eight replicate rows in each four 96-well plates scanned five times on each of 2 days. Translocation was measured as the fractional localized intensity of the nucleus (FLIN), an implementation of our more general fractional localized intensity of the compartments (FLIC), which analyzes whole compartments in the context of the entire cell. The NF kappaB antagonist assay (inhibition of IL-1- induced NF kappaB translocation) data were collected on a Q3DM (San Diego, CA) EIDAQtrade mark 100 high throughput microscopy system. [In 2003, Q3DM was purchased by Beckman Coulter Inc. (Fullerton, CA), which released the IC 100 successor to the EIDAQ 100.] The generalized FLIC method is described along with two-point (minimum-maximum) and multiple point titration statistical methods. As a ratio of compartment intensities that tend to change proportionally, FLIN was resistant to photobleaching errors. Two-point minimum-maximum statistical analyses yielded the following: a Z' of 0.174 with the data as n = 320 independent well samples; Z' by row data in a range of 0.393-0.933, with a mean of 0.766; by-plate Z' data of 0.310, 0.443, 0.545, and 0.794; and by-plate means of columns Z' data of 0.879, 0.927, 0.945, and 0.963. The mean 50% inhibitory concentration (IC50) for IL-1 receptor antagonist over all experiments was 213 ng/ml. The combined IC50 coefficients of variation (CVs) were 0.74%, 0.85%, 2.09%, and 2.52% for the four plates. Repeatability IC50 CVs were as follows: day to day 3.0%, row to row 8.0%, plate to plate 2.8%, and day to day 0.6%. The number of cells required for statistically resolvable differences in dose concentrations, plotted in a family of FLIN sigma/deltamicro (SD/range) curves and tabulated, demonstrated cell-by-cell assay precision with our combined sigma/deltamicro = 0.32 that required approximately 10-fold fewer cells than in a previously reported NF kappaB assay with sigma/deltamicro = 1.52. To better understand the relationship between cell-by-cell measurements and IC50 precision, 500 Monte Carlo simulations with varying cell-measurement SDs were used to explore three-, five-, seven-, and 11-point model titrations. The reductions in deltaIC50 90% confidence intervals from 11- to three-point titrations were 10-fold with the previously reported sigma/deltamicro = 1.52 and twofold with our sigma/deltamicro = 0.32. With these normalized parameters, this report provides a common statistical foundation, independent of the assay details, for evaluating the performance of imaging data on any instrument.
Assuntos
Transporte Ativo do Núcleo Celular/fisiologia , Bioensaio/métodos , Núcleo Celular/metabolismo , Interpretação de Imagem Assistida por Computador/métodos , Microscopia de Fluorescência/métodos , NF-kappa B/metabolismo , Receptores de Interleucina-1/antagonistas & inibidores , Sialoglicoproteínas/administração & dosagem , Transporte Ativo do Núcleo Celular/efeitos dos fármacos , Algoritmos , Contagem de Células/métodos , Núcleo Celular/ultraestrutura , Interpretação Estatística de Dados , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Células HeLa , Humanos , Proteína Antagonista do Receptor de Interleucina 1 , Transporte Proteico/efeitos dos fármacos , Transporte Proteico/fisiologia , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Software , Validação de Programas de ComputadorRESUMO
Osteopontin is a major non-collagenous bone matrix protein secreted into the mineralizing extracellular matrix by osteoblasts during bone development. Recombinant human osteopontin (hOPN) that includes the Arg-Gly-Asp (RGD) cell recognition site was expressed in Escherichia coli and the purified osteopontin increased cell adhesion, proliferation and differentiation of osteoblast cells (p<0.05).